Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

April 24, 2007

Primary Completion Date

September 1, 2010

Study Completion Date

September 1, 2010

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Exemestane

DRUG

Goserelin

DRUG

Carboplatin

Trial Locations (12)

14004

Hospital Universitario Reina Sofía, Córdoba

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

15009

Centro Oncológico Regional de Galicia, A Coruña

20014

Onkologikoa, Donostia / San Sebastian

23007

Complejo Hospitalario de Jaén, Jaén

28006

Hospital de la Princesa, Madrid

29010

Hospital Clínico Universitario Virgen de la Victoria, Málaga

46010

Hospital Clínico Universitario de Valencia, Valencia

08208

Corporació Sanitaria Parc Taulí, Sabadell

08221

Hospital Mutua de Terrassa, Terrassa

03010

Hospital General de Alicante, Alicante

08003

Hospital del Mar, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER